SCHEMBL426748

SCHEMBL426748

CCOC(=O)c1cc(-c2cccc(C#N)c2)c(-c2cccc(Cl)c2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
MAPK14 Q16539 1/20 0.45
CNR2 P34972 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
TLR8 Q9NR97 1/20 0.41
TLR7 Q9NYK1 1/20 0.41
SETD7 Q8WTS6 1/20 0.41
ALOX5 P09917 3/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10109873 0.90 TRPM8 (0.54) TRPM8MAPK14L3MBTL1KDM4EALDH1A1
SCHEMBL422503 0.89 MAPK14 (0.48) FNTAFNTBTRPM8PTGDR2MAPK14
SCHEMBL2506409 0.84 PTGDR2 (0.44) FNTAFNTBTRPM8PTGDR2CNR2
SCHEMBL424173 0.83 PTGDR2 (0.49) FNTAFNTBPTGDR2MAPK14TDP1
SCHEMBL422050 0.78 TRPM8 (0.53) TRPM8L3MBTL1KDM4EALDH1A1HPGD
SCHEMBL423837 0.78 TRPM8 (0.53) TRPM8L3MBTL1KDM4EALDH1A1HPGD
SCHEMBL420399 0.77 MAPK14 (0.51) FNTAFNTBMAPK14L3MBTL1KDM4E
SCHEMBL6018669 0.74 MAPK14 (0.65) TRPM8MAPK14L3MBTL1KDM4EALDH1A1
SCHEMBL423848 0.74 MAPK14 (0.52) FNTAFNTBPTGDR2MAPK14CNR2
SCHEMBL2505963 0.74 FNTA (0.41) FNTAFNTBTRPM8PTGDR2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 US disclosed
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 US disclosed
US-8546438-B2 Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-10-01 US disclosed
EP-2376482-B1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2013-03-06 EP disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022123-A1 SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF TPMT, MAVS, EIF2AK2 FNTA 2687/4885FNTB 2776/4885TRPM8 3898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.